Evidence map›Paper›PMID 35517889›Full record

ArticleAdvanced pharmaceutical bulletin2022

microRNA-193a-5p Suppresses the Migratory Ability of Human KATO III Gastric Cancer Cells through Inhibition of Vimentin and MMP-9.

Amir Baghbanzadeh, Elham Baghbani, Khalil Hajiasgharzadeh, Saeed Noorolyai, Vahid Khaze, Behzad Mansoori, Masoud Shirmohamadi, Behzad Baradaran, Ahad Mokhtarzadeh

Abstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amir BaghbanzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-1261-3213
Elham BaghbaniImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Khalil HajiasgharzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Saeed NoorolyaiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Vahid KhazeImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad MansooriImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Masoud ShirmohamadiLiver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-8642-6795
Ahad MokhtarzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-4515-8675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ApoptosisGastric CancerGene TherapyMigration AssaymiRNA-193a‐5p

Identifiers

PMID35517889
PMCPMC9012914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.